[Various therapy options. Medical Chemistry of platelet aggregation inhibitors].
Zettl
Heiko
H
Johann Wolfgang Goethe-Universität, Frankfurt/Main.
Schubert-Zsilavecz
Manfred
M
D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D004176:Dipyridamole / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D016285:Iloprost / Q000494:pharmacology / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011448:Prostaglandin Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D058919:Purinergic P2 Receptor Antagonists; D013927:Thrombosis / Q000188:drug therapy* / Q000517:prevention & control
D016861:Cyclooxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011448:Prostaglandin Antagonists; D058919:Purinergic P2 Receptor Antagonists; D004176:Dipyridamole; D016285:Iloprost